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Abstract
Background: Familial component is estimated to account for about 10% of ovarian cancer. However, the mode of inheritance
of ovarian cancer remains poorly understood. The goal of this study was to investigate the inheritance model that best fits the
observed transmission pattern of ovariancancer among 7669 membersof 1919 pedigrees ascertainedthrough probands from
the Gilda Radner Familial Ovarian Cancer Registry at Roswell Park Cancer Institute, Buffalo, New York.
Methodology/Principal Findings: Using the Statistical Analysis for Genetic Epidemiology program, we carried out complex
segregation analyses of ovarian cancer affection status by fitting different genetic hypothesis-based regressive multivariate
logistic models. We evaluated the likelihood of sporadic, major gene, environmental, general, and six types of Mendelian
models. Under each hypothesized model, we also estimated the susceptibility allele frequency, transmission probabilities for
the susceptibility allele, baseline susceptibility and estimates of familial association. Comparisons between models were
carried out using either maximum likelihood ratio test in the case of hierarchical models, or Akaike information criterion for
non-nested models. When assessed against sporadic model without familial association, the model with both parent-
offspring and sib-sib residual association could not be rejected. Likewise, the Mendelian dominant model that included
familial residual association provided the best-fitting for the inheritance of ovarian cancer. The estimated disease allele
frequency in the dominant model was 0.21.
Conclusions/Significance: This report provides support for a genetic role in susceptibility to ovarian cancer with a major
autosomal dominant component. This model does not preclude the possibility of polygenic inheritance of combined effects
of multiple low penetrance susceptibility alleles segregating dominantly.
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Introduction
Established genetic risk factors for epithelial ovarian cancer
(EOC) include the presence of an inherited mutation in one of the
four ovarian cancer susceptibility genes, BRCA1, BRCA2, MSH2
or MLH1 [1–6]. However, not all families with a history of ovarian
cancer will be carriers of any of these genes and, in those mutation-
positive families, on average, only one-half of at-risk women will be
carriers. In an effort to understand the role of genetic factors in the
etiology of ovarian cancer, several studies have been carried out in
different human populations [1,5,7–18]. These studies ranged from
genetic epidemiological and segregation analyses [8,14] that
investigate mutations in specific genes by molecular genetics
[10,11,13,17],to risk and survival analyses [5,12,18]among families
and pedigrees with affected relatives. Despite these studies, the
mode of inheritance of susceptibility to ovarian cancer is not
completely understood. In a recent study, members of 283 epithelial
ovarian cancer families from the United Kingdom (UK) and the
United States (US) were screened for coding sequence changes and
large genomic alterations (rearrangements and deletions) in the
BRCA1 and BRCA2 genes [19]. Of the deleterious mutations
identified in the families, 37% and 9% were found in BRCA1 and
BRCA2 genes respectively. Moreover, screening for MSH2 and
MLH1 mutations in 77 cases of familial ovarian cancer, who
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5939previously tested negative for BRCA1 and BRCA2 mutations,
revealed 2 cases with MSH2 mutations and none with a MLH1
mutation [20]. While these results indicate that BRCA1, BRCA2
and MSH2 are important susceptibility genes for ovarian cancer, it
is also clear that other susceptibility gene(s) may exist.
Segregation analysis is often a starting point for family-based
genetic studies of complex human diseases [21]. It helps to assess
the possible genetic mode of segregation of disease by consider-
ation of relevant hypothesis-based mathematical models. One
advantage of segregation analysis is that it does not strictly require
availability of genetic markers on study participants. Findings from
segregation analyses are often used to formulate tailored research
hypotheses on the disease under investigation, and/or to decide on
the type of investigative effort on the disease. This study was
therefore carried out to assess types of familial dependence in
ovarian cancer, to investigate possible evidence of transmission of
major gene(s) for ovarian cancer; and to determine the best mode
of transmission for such major gene(s) in our data on 1919
pedigrees from the Gilda Radner Familial Ovarian Cancer
Registry (GRFOCR). This study was intended to provide data
on the nature of the genetic role in the apparent familial pattern of
ovarian cancer susceptibility in this study population.
Results
Characteristics of GRFOCR members
Table 1 shows the distribution of relationship types and total
number of study subjects included in this study. Of the 7669 total
number of individuals in the data, 6213 were females and 1456
males. Of the 6213 females, 3802 were affected and 2253 unaffected
while affection status for 158 females was unknown. Individuals with
unknown affection status were retained in the data to establish
relationship within pedigrees, but were not used in the analysis
because their phenotype values were set to missing. Overall, the data
is composed of 15336 parent-offspring pairs, 4825 different sib-pairs
broken down to sister-sister (n=2900), sister-brother n=1543),
brother-brother (n=382), and half sib (n=8) pairs (Table 1). In the
second- and third-degree relative categories, there were 9742
grandparental, 2709 avuncular and 4 cousin pairs. The number of
generations per pedigree varies from 2 to 5 generations (Figure 1)
which seem to account for the large range of number of nuclear
families per pedigree and the distribution of inheritance vector bits
seen in the data (Figure 2). Among the relationship pairs, there were
1062 parent/offspring, 935 sister/sister, 2 half sib, 161 grandparen-
tal and 272 avuncular concordant for ovarian cancer (Table 2).
The BRCA1, BRCA2, MSH2, and MLH1 mutation status of a
subset of GRFOCR members was recently reported [19,22]. In
137 GRFOCR families, the frequency of BRCA1 and BRCA2
mutations was 39%. In 77 of these families negative for a BRCA1
or BRCA2 mutation, the frequency of MSH2 or MLH1 mutation
was 2.6% and 0%, respectively. These results confirm that
BRCA1, BRCA2, MSH2 and MLH1 mutations do not fully
account for familial predisposition to ovarian cancer.
Segregation analyses indicate evidence for the familial
transmission of a major gene in EOC
The parameter estimates and test statistics from the complex
segregation analyses are presented in Table 3. All analyses were
Table 1. Distribution of relationship types in the study
sample.
Relationship Count
Proband 1919
Parent: Offspring 15336
Sib-pairs 4825
Sister: Sister 2900
Sister: Brother 1543
Brother: Brother 382
Halfsib 8
Grandparental 9742
Avuncular 2709
Cousin 4
Individuals 7669 (6647)
{
Male 1456 (4025)
Female 6213 (2622)
Affected 3802
Unaffected 2253
Unknown 158
{Values in parentheses indicate number of dummy individuals used for the
purpose of pedigree connections and who were not considered in analysis.
These dummies were mostly pedigree founders.
doi:10.1371/journal.pone.0005939.t001
Figure 1. Plot showing distributions of number of generations in the 1919 pedigrees.
doi:10.1371/journal.pone.0005939.g001
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an individual will be affected) for males equal to zero. To account
for presence of other cancer types of interest, we incorporated in
our models additional covariate, but because there were only a few
individuals with such other types of cancers, the inclusion or
exclusion of the covariate had no effect on the models (data not
shown). This covariate was subsequently dropped from all analyses
reported in this study.
To determine support for familial or residual association in the
data, firstly we compared three sporadic models, each having
different type of familial association – parent-offspring, sibling or
both parent-offspring and sibling. The model with both parent-
offspring and sibling residual association fitted the data better than
either of the other two (results not shown). Secondly, we then
compared a sporadic model without residual association param-
eter (model 1) with the sporadic model that included both offspring
and sibling residual association (model 2). The model with familial
association significantly fitted the data better than the one without
(Model 2 vs. 1, x2
2 ðÞ ~65:25, pv0:0001), thereby providing
support for the existence of familial association in the data and
justification for estimation of familial association parameters in the
subsequent models.
Next, we tested the hypothesis of no major gene by comparing
the sporadic model 2 (sporadic with FA) with the general or full
model (model 12). The sporadic model was strongly rejected
(x2
5 ðÞ ~46:02, pv0:001), thus providing support for the existence
of a major gene. The hypothesis of a major gene only was tested by
comparing model 3 and model 12. Again, the hypothesis of a
major gene only was rejected (x2
4 ðÞ ~133:76, pv0:001). To
investigate possible transmission of the major gene, the hypothesis
of ‘‘no type-specific transmission’’ was assessed by comparing the
environmental model (model 10) in which transmission parameters
are constrained equal to allele frequency, with the general model
(model 12) in which transmission and allele frequency parameters
were estimated. This hypothesis of no type-specific transmission
was also rejected (Model 10 vs. 12: x2
2 ðÞ ~115:27, pv0:001). The
rejection of the environmental model is an indication of
transmission of major gene type-specific.
To establish the evidence for segregation of major gene (s), the
hypothesis of Mendelian transmission must fail to be rejected in
addition to rejection of both hypotheses of ‘‘no major effect’’ and ‘‘no
transmission of major effect’’ [23,24]. Since the last two criteria have
been met, the hypothesis of ‘‘Mendelian transmission’’ was therefore
tested by comparing all the different types of Mendelian models
(Models 4–9) with the general model. The dominant Mendelian
model (model 5) could not be rejected (x2
3 ðÞ ~1:30, p~0:729),
thereby providing supporting evidence for the transmission of major
gene with a susceptibility allele frequency of 0.21.
EOC segregates in a Mendelian dominant fashion
To further determine if the transmission probabilities of the
major gene in the data conform with Mendelian mode, we
compared the model in which only the tAB was estimated (model
11) with the Mendelian dominant model. The Akaike Information
Criterion (AIC) values indicate that the dominant model is a
better-fitting model (Model 5 (AIC=5627.23) vs. Model 11
(AIC=5760.38)). Because BRCA1, BRCA2, MSH2, and MLH1
mutations are known to be associated with elevated risk of ovarian
cancer and are transmitted in an autosomal dominant fashion, we
investigated if the observed evidence for dominant inheritance was
driven by a single or multiple loci. Using the dominant Mendelian
model, we fitted several polygenic mixed models with a parameter
for varying number of loci. The AIC value for the dominant
Mendelian model assuming three polygenic loci was the smallest
(6413.02) compared to the other models assuming two
(AIC=6441.18) or four (AIC=6424.61) polygenic loci. It is
therefore not unlikely that the observed mode consists of polygenic
Figure 2. Distributions of numbers of nuclear families and inheritance vector bit in the 1919 pedigrees.
doi:10.1371/journal.pone.0005939.g002
Table 2. Distribution of ovarian cancer affection status
among relationship pairs.
Pairs
Concordant
affected Discordant
Parent/Offspring 1062 5311
Sib-pairs
Sister/Sister 935 1156
Half Sib 2 4
Grandparental 161 2943
Avuncular 272 1455
Cousin 0 3
doi:10.1371/journal.pone.0005939.t002
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susceptibility alleles segregating dominantly. The results of this
study thus provide evidence for genetic role in the etiology of
ovarian cancer by showing support for Mendelian dominant mode
of segregation of susceptibility to epithelial ovarian cancer.
Discussion
We present here results from complex segregation analysis of
ovarian cancer susceptibility. We analyzed 1919 pedigrees derived
from the Gilda Radner Familial Ovarian Cancer Registry (formerly
referred to as the Familial Ovarian Cancer Registry) at the Roswell
Park Cancer Institute (RPCI), Buffalo, New York, USA. Each
pedigree was ascertained through affected proband and because of
the inclusion criteria discussed in details under the materials and
methods above, our sample was a little more enriched with affected
individuals possibly more than would have been seen in unselected
samples. In this study, we restricted analysis to female pedigree
members since ovarian cancer does not occur in men. To achieve
this restrictive analysis, we treated all males as unaffected and then
set the penetrance for susceptibility to ovarian cancer as zero for
males. To assess the hypothesis of no familial association, we
compared the likelihood of the sporadic model without familial
components with that inwhichparametersforboth parent-offspring
andsib-sib wereestimated.Sincetheanalyseswere restrictedtoonly
females, the parent-offspring and sib-sib parameters are interpreted
as mother-daughter and sister-sister, respectively. The model with
familial association parameters provided better fit than it’s
counterpart that did not include familial association components.
The better fitting of the model thus provided evidence of familial
association in susceptibility to ovarian cancer.
We also investigated the mode of inheritance of ovarian cancer
susceptibility; whether it was sporadic, environmental, or Mende-
lian. Although the observed aggregation of affection status in the
data points to familial association and is consistent with an
inheritance basis, we had to evaluate all relevant possible genetic
models to ascertain the most likely mode of inheritance. We
estimated the disease allele frequency alongside the susceptibility
and transmission parameters depending on specific assumption for
the models. Because all the hypothesis-based models were
hierarchical in setting, since they were nested in the most general
model, we based our statistical inferences on likelihood ratio test.
Our data indicate that (i) the sporadic model of segregation of a
major gene with familial association must be rejected when
compared to the general with familial component (ii) the
hypothesis of Mendelian transmission must be accepted in favor
of general transmission, and (iii) the hypothesis of no transmission
of a major gene must be rejected when compared to the general
transmission. We showed that both the sporadic and environmen-
tal (no transmission model) were rejected with p-values much less
than 0.001, while the autosomal dominant Mendelian model could
not be rejected against the most general model (Table 3).
In a previous study, segregation analysis of 112 high risk ovarian
cancer families found that BRCA1/2 mutations accounted for
only about one half of familial ovarian cancer (5). However, there
was little evidence that other major high-penetrance ovarian
cancer susceptibility genes explain the residual familial ovarian
cancer [5]. Although non-BRCA1/2 risk for ovarian and breast
cancers may be transmitted by different modes, a segregation
analysis of 858 families of early onset breast cancer reported a
residual dominantly inherited risk of breast cancer besides the risk
derived from mutations in BRCA1/2. [25]. In the GRFOCR,
BRCA1/2 mutations were found in 39% of 137 families tested and
MSH2 mutations were found in 2.6% of 77 families tested [19].
The limited number of families tested precluded investigating the
possible influence of BRCA1/2 mutations on the observed
dominant Mendelian mode of segregation of ovarian cancer in
the current study of 1919 GRFOCR families. Despite this
limitation, the investigations using the GRFOCR provide evidence
supporting a dominant mode of segregation of susceptibility to
Table 3. Parameter estimates from segregation analysis of ovarian cancer in 1919 proband-ascertained pedigrees.
Model parameters
Hypothesis
Model
No.
Transmission
probabilities Susceptibilities
Residual
Associations
1
qA tAA tAB tBB bAA bAB bBB ªm:d ªss df
1 -2 ln L AIC x
2 (df) P
Sporadic 1 [0]
{ –––2382.91 [=bAA][ = bAA] – – 1 5731.20 5733.20 115.27 (7) ,.001
Sporadic with FA 2 [0] – – – 2382.97 [=bAA][ = bAA] 0.04 0.68 3 5661.95 5667.95 46.02 (5) ,.001
Major Gene only 3 0.50 M
{ MM2326.08 2407.14 2326.08 – – 4 5749.69 5757.69 133.76 (4) ,.001
Codominant 4 1.00
* MMM2382.97 3.60 5.76 0.04 0.68 5 5661.95 5671.95 46.02 (3) ,.001
Dominant 5 0.21 M M M 2389.85 [=bAA] 2382.37 0.07 1.61 5 5617.23 5627.23 1.3 (3) 0.729
Recessive 6 0.94 M M M 2383.31 2255.96 [=bAB] 20.24 0.62 5 5650.12 5660.12 34.19 (3) ,.001
Additive 7 1.00
* MMM2382.97 2382.96 10.56 0.04 0.68 4 5661.95 5669.95 46.02 (4) ,.001
Decreasing 8 0.00
* M M M 7.91 7.51 2382.97 0.04 0.68 5 5661.95 5671.95 46.02 (3) ,.001
Increasing 9 1.00
* MMM2382.97 1.98 5.76 0.04 0.68 5 5661.95 5671.95 46.02 (3) ,.001
Environmental 10 0.72 [0.72] [0.72] [0.72] 2392.71 2307.48 2256.07 21.00 1.00 6 5731.20 5743.20 115.27 (2) ,.001
Tau AB free 11 0.74 [1] 0.70 [0] 2429.79 5.00 8.00 0.99 0.99 7 5746.38 5760.38 130.45 (1) ,.001
General 12 0.49 0.90 0.57 1.00
* 2393.66 0.23 0.38 1.00 1.00 8 5615.93 5631.93 – –
{Parameters in square brackets were fixed at the values indicated;
{M indicates Mendelian transmission: tAA=1.0, tAB=0.5, tBB=0.0.
1The meaning of c parameters is as follows:
c
md represents mother/daughter residual association;
c
ss represents sister/sister residual association;
*Parameter hit bound;
1No. of independent parameters: (no. of parameters in model) – (no. of parameters fixed at boundary) – (no. of dependent and or fixed parameters); Chi-square is
defined as (-2 ln L) of the data under the specific hypothesis minus (22 ln L) of the data under the general model.
doi:10.1371/journal.pone.0005939.t003
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genes besides BRCA1, BRCA2 and MSH2.
Materials and Methods
Ethics Statement
The Gilda Radner Familial Ovarian Cancer Registry: Family
and Medical History and Biosample Resource (CIC 95–27)
protocol has been reviewed and approved the Roswell Park
Cancer Institute IRB Board.
Study subjects and characteristics of family members.
Study subjects for this study were derived from the Gilda Radner
Familial Ovarian Cancer Registry (formerly referred to as the
Familial Ovarian Cancer Registry). The Gilda Radner Familial
Ovarian Cancer Registry (GRFOCR) is a self-referred Registry of
families with two or more ovarian cancer cases in blood relatives.
It was established in 1981 at the Roswell Park Cancer Institute by
Dr. M. Steven Piver to study the incidence of familial ovarian
cancer [26–29]. The primary function of the Registry is to receive
family cancer information voluntarily contributed throughout the
United States by ovarian cancer patients, referring and concerned
physicians, concerned women, and patients of the Roswell Park
Cancer Institute (RPCI) Gynecologic Oncology Department. The
objectives of the Registry include (i) obtaining detailed family
histories from individuals who are apparently from families with
two or more cases of ovarian cancer or a syndrome possibly related
to ovarian cancer; (ii) documenting through medical records and
through pathologist review of tissues the occurrence of cancer; (iii)
collecting, processing and storing biological samples, when
possible, from Registry participants; and (iv) making the
information and biological samples available for research under
Institutional Review Board approved research protocols.
Recruitment of subjects. Registry participants are recruited
through probands or index persons meeting at least one of the
following criteria: (i) family history of two or more cases of ovarian
cancer;(ii)familyhistoryof one case of ovarian cancerandtwocases
of cancer at any other site; (iii) family history of at least one female
with two or more primary tumors with one of the primaries being
ovarian cancer; (iv) family history of two or more cases of cancer
with at least one case being ovarian cancer, and the other cancer
considered to be of early onset (#45 years old). In addition to
meeting at least one of the preceding criteria, each participant is
required to sign a consent form. Individuals unable to give consent
as a result of mental, intellectual, or cognitive deficits are excluded,
however, such could appear in the Registry through collection of
family history data but without collection of bio-samples from them.
Subjects for this study consisted of 7669 adult members from 1919
differentpedigreesfromtheGRFOCR.Thefamiliesincludedinthe
present study comprised of 1412 families ascertained to have two or
more cases of ovarian cancer; 17 families with one case of ovarian
cancer and two cases of cancer at other sites; and 490 families in the
category of those having at least one female with more than one
primary tumors with one of the primaries being ovarian cancer or
having more than one case of cancer with at least one case being
ovarian cancer and the other cancer considered to be of early onset.
Data collection. Data are collected through Family History
Forms completed by subjects. In addition, subjects give
authorization to release medical records and archival tissues
(where available). Both the completed Family History Form and
retrieved medical records are reviewed to ascertain eligibility
before subjects are entered into the Registry. Information collected
on individuals who do not meet inclusion criteria at the time of
collection are not entered into the Registry, and are either
destroyed, placed in an inactive locked file, or returned to the
individuals upon request. Following formal entry into the Registry,
the individuals are provided with an epidemiologic survey form for
collection of detailed epidemiologic data and a blood donation
form for biosample collection. Permission to invite relatives is also
requested from Registry participants and letter of introduction sent
to relatives for whom permission to invite is granted. Invited
relatives who accept to participate are also asked to sign a consent
form after which they are asked to complete voluntarily all
necessary data and biosample collection forms.
Construction of pedigrees. Based on information collected
through the Family History Form, we established family and
pedigree relationship of every subject. Pedigrees used in this study
were constructed from relatives ascertained through probands
using computer codes written and implemented in SAS [30] as
macros and the resulting established pedigree relationships were
checked and corrected for possible errors using MADELINE [31]
software package. Where necessary, dummy individuals were
added to families for the purpose of connecting relatives within
pedigrees, and the affection status for such dummy individuals was
set to missing and thus they were not used in the analyses. A total
of 7669 real pedigrees members and 6647 connecting dummy
persons were included in this study.
Statistical analysis. In the present study, data used included
information on (i) sex, (ii) ovarian cancer affection status defined as
affected, unaffected or unknown; (iii) information on affection
status for other cancer site such as breast, pancreas and uterus/
endometrium, also defined as affected, unaffected or unknown;
and (iv) family/pedigree relationships. Estimation of the
distributions of relationship types and ovarian cancer affection
status among relationship pairs were performed using the
Statistical Analysis for Genetic Epidemiology (SAGE) program
PEDINFO, version 5.2 [32]. Although analyses were constrained
to female pedigree members, male relatives had to be included for
the purpose of defining pedigree relationships.
To account for proband ascertainment, ascertainment correc-
tion was applied in all segregation analyses by conditioning each
pedigree’s likelihood on the affection status of the proband.
Segregation Analysis. To explore the mode of familial
transmission of susceptibility to ovarian cancer, we performed
complex segregation analysis using the maximum likelihood method
to estimate the parameters in each of the hypothesis-based
mathematical models examined. Since the presence of a BRCA1
or BRCA2 mutation status does not preclude the presence of
additional susceptibility gene(s) which could contribute to disease
penetrance, mutation positive patients were therefore not excluded
from this analysis. The SEGREG program of SAGE, version 5.2
[32] under Linux operating system was used to fit each model. For
each model, we assumed that the presence (or absence) of the
putative disease allele influences susceptibility to ovarian cancer, and
thenappliedtheregressivemultivariatelogisticmodelforbinarytrait
as described by Karunaratne and Elston [33]. This approach
enabled us to include available covariates of interest in the fitted
models. The fitted models assumed that, conditional on the
phenotype and the major type of any individual who belongs to
two nuclear families, the likelihoods for those two nuclear families
are independent. Therefore, the marginal probability (or
susceptibility) that any pedigree member has a particular
phenotype is the same for all members who have the same values
of any covariates in the model. This susceptibility given by the
cumulative logistic function as
l~
eh i ðÞ yi
1zeh i ðÞ
Segregation Analysis
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the logit of the susceptibility for the i-th individual which is defined as
hg i ðÞ ~log
pY ~1 ðÞ
1{pY ~1 ðÞ

~bgzQX
where b is the baseline parameter; g is the latent genetic ‘‘type’’ [34]
or ‘‘ousiotype’’ [35]; and X is the covariate vector. Under a major
locus model with two alleles, A and B, A being the susceptibility allele,
the three types correspond to genotype g=AA, AB or BB transmitted
according to Mendelian mode. The corresponding baseline
parameters for susceptibility are then bAA, bAB and bBB: The
transmission parameters represented as tAA, tAB and tBB in each
model are the conditional probabilities that a parent of a given
genotype transmits the susceptibility allele A to the offspring [36,37].
T h et r a n s m i s s i o np a r a m e t e r sa n dt h ea l l e l ef r e q u e n c yp a r a m e t e r ,qA,
for the susceptibility allele are estimated alongside the three baseline
parameters for susceptibility bAA, bAB, bBB ðÞ in each model
depending on the specified assumption. For example, under the
assumption of Mendelian inheritance, the transmission parameters
are constrained to tAA~1:0, tAB~0:5 and tBB~0:0.T h e
following sporadic, environmental and genetic models were
considered in assessing type of familial association and possible
evidence of transmission of major effect.
1. Sporadic or no major gene model. In this model, both familial
association (FA) (i.e. father-mother (FM), mother–offspring
(MD), father–offspring (FO) or sibling (SS)), and transmission of
major gene (MG) (i.e. qA~0; tAA~tAB~tBB~0) are not
assumed. There is only one baseline parameter (i.e.
bAA~bAB~bBB) which is interpreted as the natural logarithm
of the odds of susceptibility versus non-susceptibility to ovarian
cancer in the absence of other factors.
2. Sporadic model with familial association. This model includes
estimation of parameters for familial association (parent-offspring
(PO) and sibling) in the absence of transmission of a major gene.
Three different models – first with only parent-offspring
parameter, second with only sibling parameter, and third with
both parent-offspring and sibling parameters, were fitted.
3. Major gene without familial association model. This model
assumes the transmission of a major gene but no familial
association. Here the susceptibility allele frequency is estimated
while the transmission parameters are constrained to the
Mendelian mode.
4. Mendelian codominant model with familial association. This
assumes transmission of a major gene and familial association.
In this and all Mendelian models tested in this study,
transmission parameters were constrained to the Mendelian
mode as tAA~1:0, tAB~0:5 and tBB~0:0. The allele
frequency, qA, familial or residual associations, cOP and fSS,
and baseline susceptibility, bAA, bAB and bBB were estimat-
ed in this and the other Mendelian models tested.
5. Mendelian dominant model which is similar to codominant
model above, except that baseline susceptibility parameters for
genotypes AA and AB are constrained equal as bAA~bAB:
6. Mendelian recessive model in which baseline susceptibility
parameters for genotypes AB and BB are constrained equal to
each other as bAB~bBB:
7. Mendelian additive model in which baseline susceptibility
parameter for genotype AB is constrained to be intermediate of
those of AA and BB as bAB~ 1
2 bAAzbBB ðÞ .
8. Mendelian decreasing model includes the assumption of
decreasing susceptibility with the maximum and minimum
susceptibility parameters constrained to genotypes AA and BB,
respectively, as bAA§bAB§bBB.
9. Mendelian increasing model is the reverse of the above
decreasing model with the baseline susceptibility parameters
constrained as bAAƒbABƒbBB:
10. Environmental model in which no transmission of suscep-
tibility allele is assumed. This is a non-Mendelian transmis-
sion model in which all the transmission probabilities are set
equal to the allele frequency as tAA~tAB~tBB~qA, but
all three susceptibility parameters bAA, bAB and bBB ðÞ are
estimated. This model assumes that the observed familial
association and segregation are both due purely to non-
transmissible environmental effects and not any major gene.
11. Tau AB free model in which transmission parameters for
genotypes AA and BB are constrained to 1 and 0,
respectively, while parameter for AB is estimated within
0–1 range as tAA~1, 0ƒtABƒ1, ~tBB~0.
12. General non-Mendelian model in which all parameters are
estimated. As a result, all other models are nested in the
general or full model and thus the general model is used as
the baseline to compare all other models in this study.
In the above models 3 to 11 where major gene is assumed, we
also assumed that the genotype frequencies are in Hardy-
Weinberg proportions (i.e, yAA~q2
A; yAB~2qA 1{qA ðÞ ;
yBB~ 1{qA ðÞ
2). Also, because ascertainment was through
probands, we corrected for ascertainment bias in each model by
conditioning the likelihood of each pedigree on the affection status
of the proband.
For testing the different hypotheses represented by the models, we
usedthelikelihoodratiotest(LRT).Sincethemodelsarehierarchical,
we tested each submodel against the general model by using the test
statistic computed as minus twice the difference between the natural
log likelihood of the general model and that of the specific submodel.
This statistic is asymptotically distributed as chi-square distribution
with degree of freedom equal to the difference in the number of
parameters estimated in both models. Using this test, a significant chi-
square indicates that the submodel tested can be rejected at the given
alpha level, which means the hypothesized model does not fit the
data. For comparison of non-nested models such as sporadic models
or Mendelian models, we used the Akaike Information Criterion
(AIC) values [38] to select the most parsimonious model for the data.
The AIC for any model is defined as [–2ln(L)+2(number of
parameters estimated in the model)]. The model with the smallest
AIC is judged the best-fitting model for the data.
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